Anna Diana

Anna Diana

Auto-generated profile, based on publicly available information

Anna Diana

TeleThon Institute of Genetics and Medicine (TIGEM), 80078 Pozzuoli, Italy

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SBSimona Brillante
Simona Brillante
MVMariagrazia Volpe
Mariagrazia Volpe
ADAnna Diana
Anna Diana
SNSantiago Negueruela
Santiago Negueruela
MMMarta Molinari
Marta Molinari
AIAlessia Indrieri
Alessia Indrieri
Stargardt disease type 1 (STGD1) is the most common hereditary macular degeneration. It is caused by mutations in ABCA4 , which result in the progressive degeneration of the retinal pigment epithelium (RPE), ultimately leading to photoreceptor loss. Despite extensive efforts, STGD1 currently lacks effective treatments. Here, we first identified mitochondrial defects in the photoreceptors of Abca4 −/− mice and STGD1 patient-derived retinal organoids. Specifically, we found reduced mitochondrial content, defective cristae morphology, and downregulation of OPA1, a critical regulator of mitochondrial integrity, demonstrating that photoreceptor defects in STGD1 also have a cell-autonomous origin, besides the RPE dysfunction. Importantly, we also demonstrated that correcting this pathological phenotype through the modulation of microRNAs 181a and b (miR-181a/b), key regulators of mitochondrial function, ameliorates the STGD1 phenotype. Indeed, genetic inactivation and adeno-associated viral vector-mediated silencing of miR-181a/b in STGD1 models restored OPA1 levels, improved mitochondrial phenotype, and reduced lipofuscin accumulation in the RPE. Our study demonstrates that mitochondrial dysfunction in photoreceptors is an important contributor to STGD1 pathology, opening promising therapeutic avenues for this disorder.

2 October 2026 in Science Advances
Verified
Journal Article
Closed access
LSLeandro R. Soria
Leandro R. Soria
ADAlfonso M. D’ALessio
Alfonso M. D’ALessio
VCVincenzo Casertano
Vincenzo Casertano
EPElena Polishchuk
Elena Polishchuk
APAndrea Pasquadibisceglie
Andrea Pasquadibisceglie
Nicola Brunetti-PierriNicola Brunetti-Pierri
Nicola Brunetti-Pierri
Nuclear glycogen storage has been known for nearly 100 years. However, its role in diseases remains unclear. Here, we found nuclear glycogen storage in livers of mice and humans with argininosuccinic aciduria (ASA), an inborn error of metabolism. Nuclear glycogenolysis sustains histone acetylation and liver homeostasis. We show that hepatic nuclear glycogenolysis is regulated by nitric oxide (NO)–dependent control of the nuclear abundance of liver glycogen phosphorylase (PYGL), an enzyme involved in glycogen breakdown that translocates from the cytosol to the nucleus. In vivo, NO supplementation restored the nuclear content of PYGL by promoting its S -nitrosylation at cysteine-446 and its nuclear translocation. Next, we found that nuclear import of PYGL is mediated by HNRNPF, a regulator of RNA maturation that shuttles between the nucleus and cytosol, thus linking control of gene expression to RNA metabolism. Similar changes were detected in both rodent and human livers with metabolic dysfunction-associated steatotic liver disease (MASLD), a global health concern with limited therapies, that shares with ASA a decrease in NO synthesis. In conclusion, our findings reveal a mechanism underlying reduced glycogenolysis and hepatic nuclear glycogen storage disorders, a new group of metabolic disorders.